Roivant Sciences ( (ROIV) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roivant Sciences shares are under pressure even as its unit Priovant reported key regulatory progress for its autoimmune drug brepocitinib. The U.S. FDA has accepted the company’s New Drug Application for treating dermatomyositis and granted a Priority Review, with an expected decision date set for the third quarter of 2026.
The late‑stage VALOR Phase 3 trial delivered positive efficacy data and showed a safety profile analysts describe as manageable. On the back of these results and the regulatory momentum, Wall Street analysts have generally moved to lift their price targets on Roivant, signaling growing confidence in the drug’s commercial potential.
More about Roivant Sciences
YTD Price Performance: 29.49%
Average Trading Volume: 7,054,781
Technical Sentiment Signal: Buy
Current Market Cap: $20.11B
For further insights into ROIV stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.